Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Previous studies have suggested that the level of residual disease at the end of therapy predicts outcome in chronic lymphocytic leukemia (CLL). However, available methods for detecting CLL cells are either insensitive or not routinely applicable. A flow cytometric assay was developed that can diffe...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Rawstron, A, Kennedy, B, Evans, P, Davies, F, Richards, S, Haynes, A, Russell, N, Hale, G, Morgan, G, Jack, A, Hillmen, P
Format:	Journal article
Język:	English
Wydane:	2001

Podobne zapisy

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
od: Hale, G, i wsp.
Wydane: (2004)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
od: Dearden, C, i wsp.
Wydane: (2011)

A novel assay for the identification of NOTCH1 PEST domain mutations in chronic lymphocytic leukemia
od: Campregher, PV, i wsp.
Wydane: (2016)

Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia.
od: Matutes, E, i wsp.
Wydane: (1999)

Purine antagonists for chronic lymphocytic leukemia: Results of a comprehensive meta-analysis
od: Steurer, M, i wsp.
Wydane: (2005)

Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief review.
od: Dicato, M, i wsp.
Wydane: (1991)

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
od: Landau, Dan A., i wsp.
Wydane: (2014)

Flowy cytometric assay for antibody to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy (CRION)
od: Kim, B, i wsp.
Wydane: (2017)

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage.
od: Clifford, R, i wsp.
Wydane: (2014)

The clinical significance of patients' sex in chronic lymphocytic leukemia.
od: Catovsky, D, i wsp.
Wydane: (2014)

State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.
od: Clifford, R, i wsp.
Wydane: (2012)

Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia.
od: Gamm, H, i wsp.
Wydane: (1988)

BRCA2 gene deletion is rare in chronic lymphocytic leukemia.
od: Pilozzi, E, i wsp.
Wydane: (1998)

Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease.
od: Senju, M, i wsp.
Wydane: (1991)

Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials
od: Geisler, C, i wsp.
Wydane: (1999)

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
od: Richards, S
Wydane: (1999)

13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia.
od: Parker, H, i wsp.
Wydane: (2011)

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
od: Skowronska, A, i wsp.
Wydane: (2012)

A multi-parametric flow cytometric assay to analyze DNA–protein interactions
od: Arbab, Mandana, i wsp.
Wydane: (2013)

A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin
od: Kulkarni, Chethana, i wsp.
Wydane: (2017)

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.
od: Chowdhury, O, i wsp.
Wydane: (2011)

Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
od: Bosanquet, A, i wsp.
Wydane: (1999)

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia
od: Berndt, S, i wsp.
Wydane: (2013)

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
od: Berndt, S, i wsp.
Wydane: (2013)

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
od: Pettitt, A, i wsp.
Wydane: (2012)

Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae.
od: Martinez, J, i wsp.
Wydane: (2006)

Genetic predisposition to chronic lymphocytic leukemia is mediated by a BMF super-enhancer polymorphism.
od: Kandaswamy, R, i wsp.
Wydane: (2017)

The Medical Research Council trials in adult acute lymphocytic leukemia.
od: Durrant, I, i wsp.
Wydane: (2000)

Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones
od: Bashford-Rogers, R, i wsp.
Wydane: (2016)

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
od: Oscier, D, i wsp.
Wydane: (2012)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
od: Else, M, i wsp.
Wydane: (2012)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
od: Lundin, J, i wsp.
Wydane: (2001)

SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
od: Wang, Lili, i wsp.
Wydane: (2014)

Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia
od: Landau, Dan A., i wsp.
Wydane: (2017)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
od: Sousos, N, i wsp.
Wydane: (2020)

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.
od: Wade, R, i wsp.
Wydane: (2011)

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.
od: Wade, R, i wsp.
Wydane: (2011)

Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?
od: Dhalla, F, i wsp.
Wydane: (2014)

Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?
od: Dhalla, F, i wsp.
Wydane: (2014)

Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials.
od: CLL Trialists’ Collaborative Group
Wydane: (2012)